AMPed up to treat prostate cancer: novel AMPK activators emerge for cancer therapy

Authors

  • Matthew J Schiewer,

    1. Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA
    2. Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA
    Search for more papers by this author
  • Karen E Knudsen

    1. Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA
    2. Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA
    3. Department of Urology, Thomas Jefferson University, Philadelphia, PA, USA
    4. Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA, USA
    Search for more papers by this author

Abstract

Despite recent advances in the treatment for metastatic prostatic adenocarcinoma, clinical management of this tumor type remains a major challenge, and there is as of yet no durable cure for advanced disease. Developing pathways that could be co-targeted alongside the androgen receptor or that would otherwise thwart the development of the CRPC is a current translational and clinical priority. In this issue, a new study by Zadra et al identifies the energy sensor AMPK (5′ AMP-activated kinase) as a viable therapeutic target in prostate cancer.

Ancillary